Several presentations at the ASCO Breast Cancer Symposium addressed important questions in triple-negative breast cancer: are there promising new treatment approaches for these patients and how can we identify which patients are high risk? More »
The new diagnostic test to detect KRAS gene mutations, will facilitate speedier assessment of the KRAS mutation status of a patient’s tumor to allow for an earlier treatment decision to use cetuximab or to go on with another treatment. More »
CancerNetwork speaks with Dr. Sara Hurvitz, director of the breast cancer program at the University of California in Los Angeles. Dr. Hurvitz is actively involved in translational phase I/II breast cancer clinical trials as well as in research to better define distinct types of breast tumors to better design novel targeted therapies. More »
Scientists in Germany have potentially found a way to indirectly target the MYC oncogene—an elusive cancer therapy target to date, discovering that cancer cells with upregulated levels of MYC are dependent on AMPK-related kinase 5 to stay alive. Inhibition of ARK5 causes these MYC-dependent cells to die. More »
A combination of cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, and temsirolimus, a mammalian target of rapamycin (mTOR) inhibitor, showed evidence of activity in refractory Ewing’s sarcoma tumors as well as small-round-cell tumors in a phase I multicenter clinical study. More »
Endocrine-therapy resistant HER2-negative breast cancer is the most common cause of breast cancer death. The basis for this resistance is heavily studied to identify new ways to treat these patients. More »
Five Steps to Improving Patient Access Judy Capko, May 21, 2013 Patient access is getting increased attention through reform initiatives. Here are five steps you can take to make sure patients get appropriate access to care in your office.